1 / 12

Radiopharmaceuticals Market to be Driven at 18.3% CAGR by Increasing Incidence of Cancer

Studying the use of radiotracers for therapeutic purposes had begun immediately after the discovery of radioactivity, however, it was not until cyclotrons became available for the acceleration of particles to fabricate radioisotopes that a significant medical application of radiotracers came into being. Radioiodine, for instance, was introduced in 1946 for treating thyroid cancer, and remains till date the most effective method for the treatment of the condition as well as hyperthyroidism.<br><br>

priyap01
Télécharger la présentation

Radiopharmaceuticals Market to be Driven at 18.3% CAGR by Increasing Incidence of Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transparency Market Research Radiopharmaceuticals Market Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018 Published Date 20-Feb-2013 127 Page Report Request Sample Buy Now Press Release http://www.transparencymarketresearch.com/pressrelease/radiopharma ceuticals-market.htm Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. Radiopharmaceuticals Market REPORT DESCRIPTION Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018 The global radiopharmaceuticals market was worth US$3.8 billion in 2011 and is expected to be growing at a stupendous CAGR of 18.3% to reach a value of US$12.2 billion by 2018.This high growth rate is calculated taking into account various market restraints such as the stringent regulatory frameworks that regulate the storage and usage of radiopharmaceuticals all over the world, a global shortage of supply, and the strengthening threat from substitute treatments. The report details the important historical benchmarks of the global radiopharmaceuticals market and the driving and restraining factors that govern it. It states the radiopharmaceuticals segment to be the largest source of revenue for the radiopharmaceuticals technologies industry. Browse Full Report with TOC: http://www.transparencymarketresearch.com/radiopharmaceuticals- market.html Radiopharmaceuticals imply the usage of radiation for non-invasive treatment and diagnosis of various diseases. Utilization of these molecules for medical purposes in PET and SPECT imaging has changed the entire algorithm of disease diagnosis. With rise in the aging population globally coupled with increasing rate of chronic cardiovascular, oncology and neurology diseases, there is tremendous growth potential in this market, especially in developing nations. Similarly, the use of radiolabeled isotopes with peptides and monoclonal antibodies has opened new boulevards for the growth of the global radiopharmaceuticals market. Many radiopharmaceuticals use technetium-99m (Tc-99m) that has many useful properties of gamma-emitting tracer nuclide. The report also analyzes the radiopharmaceuticals market by generators and by further classifying them in terms of medical isotopes, their applications, end users and geographic distribution. The medical isotopes category covers major isotopes used in SPECT and PET imaging like technetium, thallium, gallium, rhenium, yttrium and others. The applications market is further classified into diagnosis and therapy. The end user analysis is done by bifurcation of the market into hospitals and outpatient diagnostic centers. 2 Transparency Market Research

  3. Radiopharmaceuticals Market The report categorizes the global radiopharmaceuticals market on the basis of the end user applying the radiopharmaceuticals, the application of the radiopharmaceuticals, and the geographical distribution of the global market. It also categorizes the radiopharmaceutical generator market on the basis of the radioactive isotope used in it.Mo-99/Tc-99m generators took up an overwhelmingly dominant share of the global radiopharmaceuticals market, leading other segments such as Sr-82/Rb-82 generators, Ge-68/Ga-67, 68 generators, Sr-90/Y-90 generators, and W-188/Re-188 generators. Enquiry Before Buying: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213 The rise in aging population on a global scale with a decrease in the supply of the Tc-99 isotope has led to commotion in the radiopharmaceuticals market. The large number of nuclear reactors shutting down for maintenance and leakage problems has led to a decrease in the global supply of Mo-99. Additionally, demand has also increased from emerging markets like India and China due to a rise in healthcare awareness and disposable incomes. Furthermore, the decline in the supply of isotopes has led to a hike in the prices of these tests; as a consequence, they are affordable for only a few people, and would also require out-of-pocket expenditure. Every day, hospitals and clinics around the world use Tc-99 to perform over 100,000 diagnostic procedures. Browse Full Press Release @ http://www.transparencymarketresearch.com/pressrelease/radiopharmaceuticals-market.htm TABLE OF CONTENT Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology Chapter 2 Executive Summary 3 Transparency Market Research

  4. Radiopharmaceuticals Market Chapter 3 Global Radiopharmaceuticals Market Overview 3.1 Overview 3.2 Market Drivers 3.2.1 Radiopharmaceutical-Based Cancer Therapy 3.2.2 Growing Preference For Disease-Targeted Therapy 3.2.3 Increasing Awareness Of Accurate Diagnosis 3.2.4 Expanding Molecular Imaging Applications 3.3 Market Restraints 3.3.1 Strict Regulatory Guidelines For Production, Storage and Usage 3.3.2 Worldwide Supply Shortages 3.3.3 Price Sensitivity And Competitive Alternatives 3.4 Market Opportunities 3.4.1 Increasing Demand For Accurate Diagnosis and Treatment, Particularly In Emerging Markets 3.4.2 Radiopharmaceutical-Based Personalized Therapy Chapter 4 Market Definition & Supply Chain Analysis 4.1 Market Definition 4.2 Radiopharmaceutical Production : A Global Perspective 4.3 Supply Chain Analysis Chapter 5 Global Radiopharmaceutical Generators Market 5.1 Overview 5.1.1 Global Radiopharmaceutical Generators Market, By Revenue, 2010-2018 (USD Million) 5.2 Mo-99/Tc-99m Generators 4 Transparency Market Research

  5. Radiopharmaceuticals Market 5.3 Sr-82/Rb-82 Generators 5.4 Ge-68/Ga-67,68 Generators 5.5 Sr-90/Y-90 Generators 5.6 W-188/Re-188 Generators Chapter 6 Global Radiopharmaceuticals Market, By End-User Groups 6.1 Overview 6.1.1 Global Radiopharmaceuticals Market By End Users, By Revenue, 2010-2018 (USD Million) 6.2 Hospitals and Medical Centers 6.2.1 Global Radiopharmaceuticals Market By End User Groups : Hospitals and Medical Centres, 2010 – 2018 (USD Million) 6.3 Outpatient Diagnostic Centers 6.3.1 Global Radiopharmaceuticals Market By End User Groups: Diagnostic Centres, 2010 – 2018 (USD Million) Chapter 7 Global Radiopharmaceuticals Market, By Applications 7.1 Overview 7.2 Radiopharmaceuticals For Diagnosis 7.2.1 Overview 7.2.2 Radiopharmaceuticals For Diagnosis, By Technique 7.2.2.1 Single-Photon Emission Computed Tomography (SPECT) 7.2.2.1.1 Comparative Analysis: SPECT Radioisotopes Market, 2011 & 2018 (%) 7.2.2.1.2 Technetium (Tc-99m) 7.2.2.1.3 Thallium (Tl-201) 7.2.2.1.4 Gallium (Ga-67) 7.2.2.1.5 Iodine (I-123) 5 Transparency Market Research

  6. Radiopharmaceuticals Market 7.2.2.1.6 Rhenium (Re-186) 7.2.2.1.7 Yttrium (Y-90) 7.2.2.1.8 Others 7.2.2.2 Positron Emission Tomography (PET) 7.2.2.2.1 Comparative Analysis: PET Radioisotopes Market, 2011 & 2018 (%) 7.2.2.2.2 Fludeoxyglucose (18f-FDG) 7.2.2.2.3 Rubidium (Rb-82) 7.2.2.2.4 Others (Carbon-11 Choline, Nitrogen13 Ammonia) 7.2.3 Radiopharmaceuticals For Diagnosis, By Indications 7.2.3.1 Oncology 7.2.3.2 Cardiovascular 7.2.3.3 Others (Neurological, Thyroid, Gastrointestinal) 7.3 Radiopharmaceuticals For Therapy 7.3.1 Overview 7.3.2 Oncology (Systemic Therapy) 7.3.2.1 Comparative Analysis: Systemic Therapy Radioisotopes Market, 2011 & 2018 (%) 7.3.2.2 Iodine (I-131) 7.3.2.3 Yttrium (Y-90) 7.3.2.4 Samarium (Sm-153) 7.3.2.5 Strontium (Sr-89) 7.3.2.6 Rhenium (186Re) 7.3.2.7 Lutetium-177 (Lu-177) 7.3.2.8 Erbium-169 (169Er) 7.3.2.9 Others 7.3.3 Other Applications In Therapy (Cardiology, Neurology) 6 Transparency Market Research

  7. Radiopharmaceuticals Market 7.4 Theranostics Chapter 8 Global Radiopharmaceuticals Market, By Geography 8.1 Overview 8.2 North America 8.2.1 North America Radiopharmaceuticals Market - Diagnosis and Systemic Therapy, 2010-2018 (USD Million) 8.2.2 North America Diagnosis Radiopharmaceuticals Market 2010-2018 (USD Million) 8.3 Europe 8.3.1 Europe Radiopharmaceuticals Market- Diagnosis and Systemic Therapy, 2010-2018 (USD Million) 8.3.2 Europe Diagnosis Radiopharmaceuticals Market 2010-2018 (USD Million) 8.4 Asia-Pacific (Apac) 8.4.1 Asia-Pacific Radiopharmaceuticals Market- Diagnosis and Systemic Therapy, 2010-2018 (USD Million) 8.4.2 Asia-Pacific Diagnosis Radiopharmaceuticals Market 2010-2018 (USD Million) 8.5 Rest of the World (RoW) 8.5.1 RoW Radiopharmaceuticals Market- Diagnosis and Systemic Therapy, 2010-2018 (USD Million) 8.5.2 RoW Diagnosis Radiopharmaceuticals Market 2010-2018 (USD Million) Chapter 9 Market Share Analysis By Key Players 9.1 Radiopharmaceuticals Market 9.2 Generators Market Chapter 10 Recommendations 10.1 Identification and Elimination Of Barriers 10.2 Development of Total Solutions 7 Transparency Market Research

  8. Radiopharmaceuticals Market 10.3 Investing in Emerging Markets 10.4 Entering Monopoly Markets Chapter 11 Company Profiles 11.1 Cardinal Health Inc. 11.1.1 Company Overview 11.1.2 Financial Overview 11.1.3 Business Strategies 11.1.3.1 Mergers and Acquisitions 11.1.3.2 External Funding 11.1.3.3 Incorporation of Advanced Technologies to Support Business Development 11.1.4 Product Portfolio 11.1.5 Recent Developments 11.2 Covidien Plc 11.2.1 Company Overview 11.2.2 Product Portfolio 11.2.3 Financial Overview 11.2.4 Strategic Overview 11.2.4.1 Mergers and Acquisitions 11.2.4.2 Approvals 11.2.5 Recent Developments 11.3 GE Healthcare 11.3.1 Company Overview 11.3.2 Product Portfolio 11.3.3 Financial Overview 8 Transparency Market Research

  9. Radiopharmaceuticals Market 11.3.4 Strategic Overview 11.3.4.1 Mergers and Acquisitions 11.3.5 Recent Developments 11.4 IBA Group 11.4.1 Company Overview 11.4.2 Financial Overview 11.4.3 Product Portfolio 11.5 Lantheus Medical Imaging 11.5.1 Company Overview 11.5.2 Financial Overview 11.5.3 Business Strategies 11.5.3.1 Rigorous Research and Development Initiatives 11.5.3.2 Selling Generic Products to Maintain Market Share 11.5.4 Product Portfolio 11.5.4.1 Recent Developments 11.6 Monrol Nuclear Products, Inc. 11.6.1 Company Overview 11.6.2 Product Portfolio 11.6.3 Strategic Overview 11.6.3.1 Mergers and Acquisitions 11.6.3.2 Collaborations 11.6.4 Recent Developments 11.7 Nordion, Inc. 11.7.1 Company Overview 11.7.2 Product Portfolio 9 Transparency Market Research

  10. Radiopharmaceuticals Market 11.7.3 Financial Overview 11.7.4 Strategic Overview 11.7.4.1 Contracts and Agreements 11.7.4.2 Divestiture 11.7.5 Recent Developments 11.7.5.1 New Product Launch 11.8 NTP Radioisotopes (Pty) Ltd 11.8.1 Company Overview 11.8.2 Financial Overview 11.8.3 Business Strategies 11.8.3.1 Media Campaigns as a Brand Management Tool 11.8.3.2 Business Expansion through Partnerships, Collaborations and Alliances 11.8.4 Product Portfolio 11.8.5 Recent Developments 11.9 Polatom 11.9.1 Company Overview 11.9.2 Financial Overview 11.9.3 Business Strategies 11.9.3.1 Maintaining an Extensive Network of Distributors 11.9.4 Product Portfolio 11.9.5 Recent Developments 11.10 Positron Corporation 11.10.1 Company Overview 11.10.2 Product Portfolio 11.10.3 Financial Overview 10 Transparency Market Research

  11. Radiopharmaceuticals Market 11.10.4 Strategic Overview 11.10.4.1 Contracts and Agreements 11.10.4.2 Collaborations 11.10.5 Recent Developments 11.10.5.1 Grants and Licenses 11.10.5.2 Incentives 11.11 Siemens Healthcare 11.11.1 Company Overview 11.11.2 Financial Overview 11.11.3 Business Strategies 11.11.3.1 Investing In Emerging Economies 11.11.3.2 Rigorous Research and Development Initiatives 11.11.3.3 Identifying Key Growth Areas and Determining Short Term Goals (Agenda 2013) 11.11.3.4 Maintaining An Extensive Suppliers Network 11.11.4 Product Portfolio 11.11.5 Recent Developments About Us Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations. 11 Transparency Market Research

  12. Radiopharmaceuticals Market Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ 12 Transparency Market Research

More Related